GleamWall
中文EN

SIGA SIGA TECHNOLOGIES INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1010086 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-69.6%
TTM net income YoY-99.1%
TTM EPS YoY-99.0%
Revenue 3-yr CAGR14.6%
Net income 3-yr CAGR—

Margins

Gross margin54.0%
Operating margin-14.2%
Net margin1.3%
FCF margin-22.1%
EBITDA margin-13.0%

Returns

ROE0.4%
ROA0.3%
ROIC (approx.)-15.0%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets5.4%
Debt / equity0.00x
Current ratio24.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-16.81x
Accruals ratio6.0%
Payout ratio6,325.2%
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.32M$41.00M$6.24M$3.79M$2.62M$81.12M$7.04M$81.47M
Cost of revenue$575,660$17.56M$2.94M$2.99M$1.00M$25.55M$157,738$14.13M
Gross profit$741,305$23.44M$3.30M$804,474$1.62M$55.57M$6.88M$67.34M
R&D expense$2.64M$4.39M$3.95M$5.04M$7.05M$4.40M$3.46M$3.34M
SG&A expense$4.62M$5.15M$4.67M$5.26M$4.79M$5.49M$5.68M$6.91M
Operating income-$6.52M$13.91M-$5.32M-$9.50M-$10.22M$45.68M-$2.26M$57.09M
Pretax income-$5.48M$14.85M-$4.04M-$7.96M-$8.36M$47.27M-$570,415$58.58M
Income tax-$2.59M$2.39M-$589,432-$2.53M-$1.99M$11.79M-$162,192$12.82M
Net income-$2.89M$12.46M-$3.45M-$5.43M-$6.37M$35.48M-$408,223$45.76M
EBITDA-$6.37M$14.06M-$5.17M-$9.35M-$10.08M$45.82M-$2.12M$57.22M
EPS (basic)-0.040.17-0.05—-0.090.50-0.01—
EPS (diluted)-0.040.17-0.05—-0.090.49-0.01—
Dividends declared per share0.600.600.600.000.000.60—0.00
Weighted avg. shares (diluted)71.85M71.88M71.65M—71.60M71.75M71.43M—
Balance sheet
Cash & equivalents$116.38M$117.58M$145.56M$154.97M$171.96M$182.46M$162.27M$155.40M
Receivables$2.02M$7.17M$4.50M$3.26M$2.49M$6.49M$7.19M$21.17M
Inventory$41.59M$41.11M$56.49M$49.05M$48.01M$35.62M$59.06M$49.56M
Current assets$165.54M$170.38M$211.53M$212.86M$227.75M$229.20M$233.62M$231.04M
PP&E, net$1.38M$1.53M$1.67M$1.09M$1.20M$1.05M$1.19M$1.30M
Goodwill$898,334$898,334$898,334$898,334$898,334$898,334$898,334$898,334
Total assets$172.65M$175.74M$219.39M$219.47M$231.60M$235.33M$247.07M$244.34M
Current liabilities$6.74M$7.85M$65.16M$17.99M$24.84M$22.72M$27.80M$25.33M
Total liabilities$9.39M$10.45M$67.77M$20.65M$28.12M$26.02M$30.93M$28.53M
Shareholders' equity$163.25M$165.29M$151.62M$198.82M$203.48M$209.31M$216.13M$215.80M
Shares outstanding71.86M71.84M71.72M71.61M71.61M71.54M71.44M71.40M
Cash flow statement
Operating cash flow-$1.18M$15.17M-$8.66M-$16.86M-$9.81M$63.08M$7.06M$56.31M
Capital expenditure$0$0$0$40,539$289,576$1$24,893$17,838
Free cash flow-$1.18M$15.17M-$8.66M-$16.90M-$10.10M$63.08M$7.04M$56.29M
Investing cash flow$0$0$0-$40,539-$289,576-$1-$24,893-$17,838
Financing cash flow-$22,480-$43.15M-$740,377-$87,823-$403,480-$42.89M-$166,193-$161,756
Depreciation & amortization$154,793$152,219$149,949$146,518$141,795$138,986$135,308$130,729
Stock-based compensation$860,302$1.21M$752,965$772,540$774,104$1.23M$902,280$764,070
Dividends paid$9,000$43.15M$159,380$87,823$162,023$42.87M$0$0
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.